Cory Perugino, MD, shares what we do and don’t know about IgG4-RD inflammation, its long-term effects, and opportunities for treatment.
Transcript
I love this question. I think it’s a really important one, and we definitely don’t know the answer yet. Damage is a major problem in IgG4-related disease and causes significant morbidity. As with many autoimmune diseases, we try to prevent it by treating effectively, maintaining remission, and treating early.
At this point, we’re still in the early stages of understanding damage. We have a general sense of what it looks like, but there hasn’t been much systematic work to define it—for example, setting out organ-specific criteria. There’s no global consensus yet on how to study it. For now, we’re describing damage; then we can refine those descriptions and identify risk factors.
An important challenge is that we don’t know when damage occurs. Does it happen early, before patients are diagnosed—during the year or two after the disease begins? Or does it develop during monitoring? We follow patients with blood work and imaging, and often adjust treatment when lab results change or symptoms arise. We don’t know whether that approach prevents damage from accumulating over time. I’d like to think it does, but we haven’t demonstrated that yet.
We also don’t know whether persistently elevated IgG4 after treatment, in the absence of obvious clinical disease—such as enlarged, swollen, or clearly inflamed organs—could reflect microscopic inflammation that leads to damage. We have much more to learn: first, how to define and describe damage, and then when and how it occurs. There are still many questions to answer.